US Patent No. 9,080,215

MicroRNAs differentially expressed in cervical cancer and uses thereof
Jul 23, 2015

Asuragen has been awarded US Patent No. 9,080,215, "MicroRNAs differentially expressed in cervical cancer and uses thereof."

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.